PAVmed (PAVM) said Tuesday it regained compliance with Nasdaq's continued listing standards for primary equity securities.
The medical technology company said it received a notification on Friday from Nasdaq stating its securities will continue to be listed and traded on the stock exchange.
PAVmed will be under a mandatory panel monitor for one year, during which any failure to meet stockholders' equity requirements will trigger a delisting notice, requiring immediate action and possibly a new hearing, the company said.
Shares of PAVmed were up nearly 6% in recent Tuesday trading.
Price: 0.84, Change: +0.05, Percent Change: +5.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.